STOCK TITAN

Rhythm Pharmaceuticals (RYTM) CSO exercises RSUs, 2,150 shares withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Rhythm Pharmaceuticals Chief Scientific Officer Alastair Garfield reported routine equity compensation activity involving restricted stock units and related tax withholding. On July 1, 2026, he exercised 4,445 restricted stock units, each converting into one share of common stock, increasing his direct common stock holdings to 12,208 shares.

To cover withholding taxes on this vesting, 2,150 common shares were withheld, classified as a tax-withholding disposition rather than an open-market sale. Following these transactions, Garfield also holds 8,888 restricted stock units, which vest in four equal annual installments of 25% each starting from July 1, 2024, contingent on his continued service.

Positive

  • None.

Negative

  • None.
Insider Garfield Alastair
Role Chief Scientific Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 4,445 $0.00 --
Exercise Common Stock 4,445 $0.00 --
Tax Withholding Common Stock 2,150 $110.41 $237K
Holdings After Transaction: Restricted Stock Units — 8,888 shares (Direct, null); Common Stock — 12,208 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.
RSUs exercised 4,445 units Restricted stock units converted into common stock on July 1, 2026
Shares withheld for taxes 2,150 shares Common shares withheld to cover vesting-related withholding taxes
Common shares held after transactions 12,208 shares Direct common stock ownership following July 1, 2026 entries
RSUs outstanding 8,888 units Remaining restricted stock units after the reported vesting and conversion
RSU-for-share ratio 1 unit : 1 share Each restricted stock unit represents one share of common stock
Annual vesting rate 25% per year RSUs vest in four equal installments from July 1, 2024
restricted stock units financial
"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax-withholding disposition financial
"These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein."
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
vesting financial
"The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Garfield Alastair

(Last)(First)(Middle)
222 BERKELEY STREET, 12TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026M4,445A(1)12,208D
Common Stock07/01/2026F(2)2,150D$110.4110,058D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)07/01/2026M4,445 (3) (3)Common Stock4,445$08,888D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
2. These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein.
3. The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.
/s/ Stephen Vander Stoep, attorney-in-fact for Alastair Garfield07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Rhythm Pharmaceuticals (RYTM) report for Alastair Garfield?

Rhythm Pharmaceuticals reported that Chief Scientific Officer Alastair Garfield exercised 4,445 restricted stock units into common stock. The transaction reflects equity compensation vesting rather than an open-market purchase or sale, and is part of his ongoing stock-based compensation package.

How many Rhythm Pharmaceuticals (RYTM) shares were involved in Alastair Garfield’s Form 4 filing?

The filing shows 4,445 restricted stock units converted into an equal number of common shares, while 2,150 common shares were withheld for taxes. After these entries, Garfield directly holds 12,208 common shares plus 8,888 remaining restricted stock units.

Were Alastair Garfield’s Rhythm Pharmaceuticals (RYTM) transactions open-market sales?

No, the Form 4 classifies 2,150 shares as a tax-withholding disposition to pay vesting-related taxes, not an open-market sale. The main action is exercising 4,445 restricted stock units into common shares as part of his compensation program.

What are the vesting terms of Alastair Garfield’s Rhythm Pharmaceuticals (RYTM) restricted stock units?

The restricted stock units vest in four equal installments of 25% each on the first four anniversaries of July 1, 2024. Vesting is conditioned on Garfield’s continued service with Rhythm Pharmaceuticals on each applicable vesting date.

How many Rhythm Pharmaceuticals (RYTM) restricted stock units does Alastair Garfield still hold after this filing?

After the July 1, 2026 transactions, Garfield holds 8,888 restricted stock units. Each unit represents a contingent right to receive one share of Rhythm Pharmaceuticals common stock, subject to the specified time-based vesting and continued service conditions.